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Neuropathic pain is a debilitating pathological condition of high clinical relevance. Changes in neuronal excitabil-
ity in the anterior cingulate cortex (ACC) play a central role in the negative emotional and affective aspects of
chronic pain.We evaluated the effects of LP-211, a new serotonin-receptor-type-7 (5-HT7R) agonist that crosses
the blood-brain barrier, on ACC neurons in amousemodel of neuropathic pain. LP-211 reduced synaptic integra-
tion in layer 5 pyramidal neurons, which was enhanced in neuropathic pain due to a dysfunction of dendritic hy-
perpolarization-activated-and-cyclic-nucleotide-regulated (HCN) channels. Acute injection of LP-211 had an
analgesic effect, increasing the mechanical withdrawal threshold in neuropathic animals, which was partially
mediated by an action in the ACC. Additionally, the acute application of LP-211 blocked the switch in the place
escape/avoidance behavior induced by noxious stimuli. Thus systemic treatment with a 5-HT7R agonist leads
to modulation of the ACC, which dampens sensory and affective aspects of chronic pain.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The anterior cingulate cortex (ACC) is one of the key brain regions
for the processing of pain (Basbaum et al., 2009; Devinsky et al., 1995;
Zhuo, 2008). It is associated with encoding the emotional and aversive
aspects of pain and it might be linked to the comorbid symptoms of
chronic pain like depression (Barthas et al., 2015), lack of motivation
(Navratilova and Porreca, 2014) and anxiety (Zhuo, 2016). Changes in
the neuronal activity in this brain area are thought to be causally linked
to the development of neuropathic pain (Baliki et al., 2012). According-
ly, hyperactivity has been observed in the human ACC in chronic pain
states (Apkarian et al., 2009). On the cellular and network level a num-
ber of plastic changes induced by neuropathic pain have been described
in the ACC ranging from increased cellular excitability and network
restructuring (Blom et al., 2014) to malfunctioning synaptic plasticity
mechanisms to promote hyperexcitability (Li et al., 2010). Recently
we found that neuropathic pain causes a functional downregulation of
hyperpolarization-activated-and-cyclic-nucleotide-regulated (HCN)
channels in the dendrites of layer 5 (L5) pyramidal neurons in the ACC
leading to cellular hyperexcitability due to enhanced dendritic integra-
tion of excitatory postsynaptic potentials (EPSPs) (Santello and Nevian,
2015). This malfunction of HCN channels in pyramidal neurons in the
chronic pain condition was recently conﬁrmed by a number of studies
(Cordeiro Matos et al., 2015; Gao et al., 2016).
Therefore, targeting the ACC for a recovery of the pathologically en-
hanced neuronal activity might be a valid strategy to alleviate the emo-
tional aspects of the neuropathic pain condition (Zhuo, 2008). Several
pharmacological interventions or neuronal manipulations in the ACC
have been proven effective in alleviating neuropathic pain behaviors
(Gu et al., 2015; Li et al., 2010; Qu et al., 2011; Santello and Nevian,
2015). Particularly, approaches that utilize the brain's neuromodulatory
systemsmight be a promising strategy for pain treatmentwithout inter-
feringwith other essential signaling pathways in the brain (Santello and
Nevian, 2015). Yet, a way to achieve neuromodulation in the ACC in be-
having animals in a non-invasivemanner is still lacking.We took advan-
tage of the new brain penetrant 5-HT7 receptor agonist LP-211 (Adriani
et al., 2012; Hedlund et al., 2010; Leopoldo et al., 2008) to modulate
neuronal activity and to evaluate its potential therapeutic effect on neu-
ropathic pain behaviors.
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2. Materials and methods
2.1. Neuropathic pain model
All the experiments were conducted after the approval of the Bern
cantonal veterinary ofﬁce (Switzerland). Only adult C57BL/6 male
mice (8–12 weeks) were used. Mice were housed in groups of 5 in
non-ﬁltered cages, with a non-inverted 12 h day-night cycle and food/
drink ad libitum. Mice were deeply anesthetized (Isoﬂurane) and then
maintained with lower anesthesia concentration (1–1.5%) during the
surgery. The surgeries were conducted under a sterile hood with lami-
nar air ﬂow. Temperature was maintained constant using an electric
heating pad with rectal probe. The eyes were maintained humidiﬁed
with the application of eye drops (Alcon, Switzerland). After the remov-
al of the fur with a depilatory cream (Veet, Reckitt Benckiser, Switzer-
land), an incision on the left posterior thigh was made to allow the
Chronic Constriction Injury of the exposed sciatic nerve through three
loose ligations 1 mm apart (5-0 Sofsilk tread - US Surgicals). Animals
whose nerve was exposed but left untouched were used as control
group (sham). The wound was sutured using 4-0 coated VICRYL rapid
suture (Ethicon). The animals recovered from the surgery after ~5 min
and did not receive any postoperative analgesic treatment.
2.2. Von Frey test
The mechanical sensitization caused by CCI surgery was assessed
using the electronic Von Frey ﬁlament test (IITC Life Science). To record
the mechanical threshold the mice were habituated in a room at 20–
23 °C with basal noise levels on a metal grid for ~30 min and then
tested with the application of the Von Frey ﬁlament on the central
plantar paw until the spontaneous retraction was detected. Six mea-
sures per each pawwere averaged to verify the development of theme-
chanical hyperalgesia. CCI mice were tested at−4,−1, +3, +6 days
from the surgery.
Von Frey testing was used to assess the modulation of the mechan-
ical hypersensitivity by LP-211 treatment in the CCI pain model. In
these experiments the animals were tested with the following time
course: day −4, +7 relative to the surgery and +30, +60, +90,
+120, +150, +180 min after the injection. When we performed the
brain injection of SB-269970 together with i.p. injection of LP-211 or sa-
line, the time course followed with the Von Frey testing was −4,
+7 days relative to the surgery and +30, +45, +60, +90,
+120 min from the end of the brain injection.
2.3. Acute brain slice preparation and patch-clamp electrophysiology
300 μm-thick coronal ACC brain slices were obtained from CCI or
Sham mice 7 to 10 days after the surgery. Anesthetized animals were
decapitated and the brain was quickly removed from the skull and
maintained in ice-cold oxygenated (95% O2 and 5% CO2) slicing solution
(65 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 25 mM NaHCO3, 7 mM
MgCl2, 0.5mMCaCl2, 25mMglucose, and 105mM sucrose) for the slic-
ing procedure. Brains were mounted on a vibratome (HM 650, Micron)
inside a slicing chamber containing the same ice-cold solution. Slices
were then transferred into aCSF solution (125 mM NaCl, 2.5 mM KCl,
1.25 mM NaH2PO4, 25 mM NaHCO3, 1 mM MgCl2, 2 mM CaCl2, and
25 mM glucose) at 34 °C for 45 min and then at room temperature
until use.
All the electrophysiological experimentswere conducted on animals
thatwere before testedwith the electronic Von Frey ﬁlament and all the
recordings were performed at 32–33 °C using aCSF as above. The re-
cordings were conducted on rostroventral ACC pyramidal cell of the
layer 5 (1.1–1.4 mm below the pial surface, 1.1–0.2 mm rostral to the
Bregma and contralateral to the lesion) with a Leica DMLFS microscope
(63× water-immersion objective), oblique illumination and CCD cam-
era. The selection of the pyramidal cells to patch was based on their
somatic morphology and on the presence of clearly visible thick apical
dendrite. Recording pipettes with a thick borosilicate wall (resistance
5–9 MΩ) were used. The dendritic patch clamp, always performed
near themain apical bifurcation, was achievedwith 15–17MΩ pipettes
with the same intracellular solution (130 mM potassium gluconate,
5 mM KCl, 10 mM HEPES, 10 mM Na+-phosphocreatine, 4 mM
Mg2+-ATP, 0.3 mM Na+-GTP, 0.2% biocytin (pH 7.3)). Biocytin was
used to allow the cell reconstruction after PFA ﬁxation (avidin-biotin-
peroxidase method (Egger et al., 2008; Sieber et al., 2013)).
Data were acquired with a Dagan BCV-700A ampliﬁer (Dagan Cor-
poration, Minneapolis, MN, USA). Signals were digitized with an ITC-
18 board (HEKA Electronics, Lambrecht, Germany). Electrode capaci-
tance and series resistancewas compensated at the beginning of the re-
cording and regularly checked and readjusted. Voltage was ﬁltered at
5 kHz and digitalized at 10 kHz. Focal electrical synaptic stimulation
was achieved by placing a theta patch-pipette located in the inner
layer 1, 30–80 μm lateral to themain apical dendrite. Stimulation inten-
sity was manually adjusted (usually 1–3 V) to obtain a stable baseline
(average amplitude 5.42 ± 0.58 mV). LP-211 was bath-applied at the
concentration of 27 nM. After recording, pipettes were gently retracted
and slices were placed in 4% paraformaldehyde (PFA). Slices were de-
veloped with the avidin-biotinperoxidase method and mounted on
cover slides. Neurolucida reconstructions were performed to reveal
the morphology of the cells. Axonal projections were omitted.
2.4. Immunohistochemistry and ﬂuorescence imaging
5-HT7 and HCN channels were co-stained to allow the visualization
of the pattern of expression in the cortical layers of the ACC. Brain slices
for ﬂuorescent immunohistochemical double labeling were prepared
from perfusion-ﬁxed brains and staining procedures described by
(Nolan et al., 2007; Santoro et al., 2009) were used. Animals were anes-
thetized with ketamine/xylazine and cardially perfused with PBS,
followed by 4% PFA diluted in PBS. Fixed brains were removed and
postﬁxed in 4% PFA at 4 °C overnight. After washing the brain with
PBS (4 × 10 min), 50 um thick coronal brain slices were prepared and
permeabilized in PBS containing 0.1% Triton-X100 (3 × 10 min). For
double immunolabeling of HCN channels and 5HT7 receptors, slices
were incubated for 1 h in a blocking buffer containing 5% normal chick-
en serum (NCS) and then simultaneously incubated in goat polyclonal
anti-HCN1 (Santa Cruz, sc-19706; 1:250) and rabbit polyclonal anti-
5HT7 (Novus, NBP1-46598; 1:250) in NCS blocking buffer overnight.
After primary incubation, sliceswerewashed in PBS containing 0.1% Tri-
ton-X100 (3 × 10 min) and incubated in ﬂuorescence conjugated sec-
ondary antisera (Alexa-594 chicken anti-goat IgG; Life Technologies,
A21468; 1:500 and Alexa-488 chicken anti-rabbit IgG; Life Technolo-
gies, A21441; 1:100) in NCS blocking buffer at room temperature for
3 h. After further washing with PBS containing 0.1% Triton-X100
(1 × 10 min) and washing in PBS (3 × 10 min), slices were embed-
ded in UltraCruz mounting medium on microscopy slides. Fluores-
cently labeled coronal brain slices were imaged using a confocal
microscope (Leica SP8) equipped with a white-light laser and two
GaAsP-detectors (HyD). Imaging was performed with a 20× objec-
tive (Leica, HC PL APO, 20×, NA 0.75 IMM CORR CS2) from the ros-
tral ACC. In control experiments, slices were treated similarly, but
the primary antibodies were omitted. No unspeciﬁc staining was
observed in this case. Speciﬁcity of the 5-HT7R antibody was further
asserted by detecting no speciﬁc staining (i.e. of apical dendrites) in
other selected brain areas.
2.5. In vivo drug testing
LP-211wasmaintained in stock solutionwith ethanol and then used
diluted in saline (NaCl 0.9%). SB-269970 was bilaterally injected in the
brain (0.5 μl per injection site, 100 μM) in solution with Alexa-594 hy-
drazide (100 μM) and aCSF.
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All the pharmacological in-vivo treatments were performed on CCI
animals tested with the Von Frey electronic ﬁlaments 7–10 days after
the CCI surgery to verify the development of the mechanical allodynia
and to ﬁnd the reference baseline for the comparison with the drug ef-
fect. i.p. injections were performed in lightly anesthetize mice (1%
Isoﬂurane) to avoid any stress which could have an impact on the be-
havioral result. Brain injections were performed on isoﬂurane anesthe-
tized animals (2%), which were head ﬁxed to allow the incision of the
scalp and the exposure of the skull. Two holeswere drilledwith a dental
drill (Osada electronics, Tokyo, Japan) above the ACC (0.70 mm rostral
and 0.35 mm lateral from Bregma,) or above the hindpaw S1 region
(−0.70 mm caudal and 1.95 mm lateral from Bregma). A micromanip-
ulatorwas used to position themicropipette in place and an air pressure
system was used to control the injection speed. Injections were per-
formed at 1.95 mm depth from the skull for the ACC and 1 mm depth
for S1 respectively. Injection site was post hoc veriﬁed by brain clearing
and light sheet imaging (Santello and Nevian, 2015).
In the LP-211 + SB-269970 experiments, the i.p. injection of LP-211
was done 20 min before the brain injection of SB-269970.
2.6. Place escape/avoidance paradigm
Experiments were conducted on CCImice 7–8 days after surgery be-
tween 10 a.m. and 15 p.m. The temperature of the behavior room was
between 20 and 23 °C with a basal noise level. Always the same exper-
imenter alone tested the animals. A cold light lamp pointing at the ceil-
ing of the room was used to diffusely illuminate the room. An open-air
custom built two compartment box (40.5 × 29.5 × 25 cm3) was used
for the place escape/avoidance paradigm (PEAP) experiment. The box
was positioned on a metal grid to allow for hind paw stimulation. One
compartment had transparent walls and the other black walls. The
two compartments were separated by a door of 7 × 7 cm allowing
free movement of the mouse between the dark and light side. The illu-
mination was set to 180 LUX intensity. Some experiments were con-
ducted at lower light intensity (~10 LUX) but we observed no
difference in the resulting data. Thus, the two groups were pooled to-
gether. The bottom of the chamber was illuminated with an IR lamp
(46×66 cm2) allowing high contrast recording of the position of the an-
imal by an IR camera. For each experiment themousewas gently put in-
side the light compartment and the recording session was immediately
started (total of 40 min). The test consisted of 10 min recording of free
exploration followed by 30 min of paw stimulation according to the
chamber the animal was in. The hind paws were stimulated every 15 s
with a Von Frey ﬁlament (number 12). The uninjured paw was stimu-
lated in the light compartment and the injured paw was stimulated in
the dark compartment. The entire course of the experimentwas record-
ed and analyzed using EthoVision XT (Noldus). The time spent in each
compartment was determined in bins of 10 min and expressed as per-
centage of the time spent in the light compartment. The PEAP test of an-
imals injected with LP-211 was started 1 h 40 min after the injection of
the drug in order to reach its peak effect during the behavioral test.
2.7. Brain clearing
Isoﬂurane anesthetized mice were decapitated and the extracted
brain was brieﬂy washed in PBS and post-ﬁxed in PFA 4% for 2 days at
4 °C. After 3washings of 10min in PBS,we applied the dehydration pro-
tocol with series of 30%, 50%, 70%, 80%, 95% and twice 100% EtOH
washes. The brains were then processed for the clearing treatment
and 3D–ultramicroscopy imaging using a LaVision Lightsheet micro-
scope (Santello and Nevian, 2015).
2.8. Data analysis
Electrophysiological recordings were acquired with IgorPro
(Wavemetrics) and analyzed with custom written Igor procedures.
The sag ratio was calculated with the equation sag ratio = (Vbaseline
− Vmin) / (Vbaseline− Vsteady-state) where Vbaseline is the resting mem-
brane potential, Vmin is theminimumvoltage reached soon after the hy-
perpolarizing current pulse and Vsteady-state is the voltage recorded a few
milliseconds before the endof the stimulus. For simplicity, Vmax refers to
Vbaseline− Vmin and VSS (steady-state) refers to Vbaseline− Vsteady-state in
the ﬁgures.
EPSP amplitude and integral and coefﬁcient of variation (CV2) were
evaluated by averaging 10 seeps before and at least 15 min after LP-211
bath application (inter-stimulus interval 10 s). Paired-pulse ratio was
calculated by averaging 4 sweeps (inter-stimulus interval 20 s). The in-
verse of the square CV was calculated by 1/CV2 = m2/σ2, with m being
the average EPSP amplitude and σ the SD.
The antihyperalgesic drug effect was quantiﬁed from the ratio of the
left to right hind pawwithdrawal thresholds as follows: (Et− Epredrug) /
Epredrug with Et being the average ratio of the time points around the
maximal antihyperalgesic effect. In particular, for the I.P. injection of
LP-211 the 2 h timepoint was considered and for the I.P. injection of
LP-211 + SB/Saline in the ACC and S1 the average between 30 and
45 min was considered.
Acquisition of the PEAP experiments was performed with Noldus
EthoVision XT software. A speed threshold (2.5 cm/s) was applied to
the last 10min average of each acquisition session to verify that the an-
imal had not been affected by the manipulation.
Statistical analysis was performed in Excel (Microsoft) and Prism
(Graphpad) using paired or unpaired Student's t-test and or one-way
RM-ANOVA for in vivo drug injections. Statistical signiﬁcance was as-
sumed for p b 0.05. Error bars represent the standard error of the
mean (SEM).
2.9. Chemicals and solutions used
LP-211 (N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazine
hexanamide) was synthetized at the Department of Pharmacy, Univer-
sity of Bari “A.Moro” Bari, Italy and used for the in-vivo experiments at a
concentration of 10 mg/kg and for patch-clamp experiments at 27 nM.
A subset of PEAP experiments were conducted with 2.5 mg/kg LP-211
injection but the results did not differ from the 10mg/kg concentration
so they were pulled together for the statistical analysis. For the
brain injection, the serotonin receptor antagonist (2R)-1-((3-
Hydroxyphenyl)sulfonyl)-2-(2-(4-methyl-1-piperidinyl)ethyl)
pyrrolidine hydrochloride (SB-269970, Sigma) was used at 100
μM. Alexa-594 hydrazide was obtained from Life Technologies
(A-10438). All the chemicals for the electrophysiology solu-
tions were obtained from Tocris.
3. Results
3.1. The brain-penetrant 5-HT7R agonist LP-211 modulates dendritic HCN
channels in ACC neurons
HCN channels are highly enriched in the apical dendrites on layer 5
(L5) pyramidal cells throughout the neocortex and they are subjected to
modulation by activation of several G protein coupled receptors (He et
al., 2014; Postea and Biel, 2011). We have recently identiﬁed a speciﬁc
receptor, the serotonin type 7 receptor (5-HT7R), which enhances den-
dritic HCN channel function of L5 pyramidal neurons in the ACC by ele-
vating cAMP levels (Santello and Nevian, 2015). Immunohistochemical
labeling of 5-HT7R and HCN1 revealed a co-localization in the apical
dendrites of L5 pyramidal cells in the ACC (Fig. 1A, B), pointing to a func-
tional coupling between 5-HT7R activation and HCN channel modula-
tion. Neuropathic pain caused by chronic constriction injury (CCI) of
the left sciatic nerve results in a down regulation of HCN channels in
the apical dendrites (Santello and Nevian, 2015). We investigated if
this pathological change concomitantly inﬂuenced the distribution of
5-HT7Rs. Within one week after the peripheral nerve ligation, CCI
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animals developedmechanical hypersensitivity restricted to the injured
hind paw, which was not present in sham-operated mice (sham) (Fig.
1C). At this time point, we derived ﬂuorescence intensity proﬁles from
double immunohistochemical labeling of HCN channels and 5-HT7Rs
from brain slices of sham (n = 9 slices from 4 animals) and CCI (n =
9 slices from 4 animals) animals. HCN channel labeling showed a char-
acteristic decrease from distal to proximal dendritic compartments,
which was well ﬁtted by a single exponential. The corresponding ﬂuo-
rescence length constant λHCN was signiﬁcantly shorter in CCI as com-
pared to sham animals (Fig. 1D, CCI 36.4 ± 1.4 μm, sham 46.0 ± 1.7
μm; p b 0.001) conﬁrming our previous results (Santello and Nevian,
2015). 5-HT7R labeling showed a Gaussian distribution in the distal api-
cal dendrites with a peak in L2/3. The peak intensity and the width of
this distribution were similar in CCI and sham (Fig. 1E, intensity: CCI
9.4 ± 1.2, sham 9.0 ± 1.4; p = 0.83; width: CCI 76.0 ± 6.1 μm, sham
78.7 ± 3.4 μm; p = 0.74) suggesting no apparent plasticity of 5-HT7Rs.
In order to test now if the novel, brain-penetrant and highly selective
5-HT7R agonist LP-211 has a similar modulatory effect on HCN channel
function as previously shown with the less potent 5-HT7R agonist 5-CT,
we performed direct dendritic patch-clamp recordings in brain slices
from the dendrites of L5 pyramidal neurons in the ACC of adult animals
that had been subjected to CCI. Bath application of LP-211 induced a sig-
niﬁcant depolarization of the dendritic membrane potential (baseline
−66.16±1.33mV; LP-211−64.96±1.21mV, n=5; p b 0.05). In par-
allel, the voltage sag in response to a hyperpolarizing current step in-
creased (baseline 1.37 ± 0.07, LP-211 1.5 ± 0.08, n = 5; p b 0.05),
indicating an enhancement of HCN channel function (Fig. 2A–C). Impor-
tantly, LP-211 had no inﬂuence on synaptic function, i.e. no inﬂuence on
the amplitude or coefﬁcient of variation of evoked EPSPs (Fig. 2D, E, am-
plitude: baseline 5.42± 0.57mV, LP-211 5.26± 0.56mV; CV2: baseline
29.59 ± 1.14, LP-211 22.67 ± 4.06, n = 10; p N 0.05), suggesting no
modulation of pre- and post-synaptic function by 5-HT7Rs. Instead, we
noticed a reduction in the single EPSP integral (baseline 143 ±
16 ms·mV, LP-211128 ± 16 ms·mV, n = 10; p b 0.05) as well as a re-
duction in EPSP summation, evaluated from the paired-pulse ratio of
two EPSPs evoked at 50 Hz (Fig. 2F, second/ﬁrst amplitude: baseline
2.10 ± 1.0, LP-211 1.73 ± 0.12, n = 10; p b 0.05). These results sug-
gested that activation of 5-HT7Rs by LP-211 lead to an increase in HCN
channel function resulting in accelerated EPSP repolarization and a re-
duction in dendritic integration.
3.2. LP-211 is more effective in modulation of HCN channels than 5-CT
Bath application of LP-211 had a signiﬁcant effect on the sag ratio
measured with somatic whole-cell recordings (Fig. 3A, B). We found
an increase in the somatic sag ratio in these experiments (baseline
1.26 ± 0.02, LP-211 1.31 ± 0.02, n = 18; p b 0.05) that was not ob-
served with the 5-HT7 agonist 5-CT (baseline 1.27 ± 0.02, 5-CT 1.24 ±
0.02, n = 10; p = 0.08). Indeed, there was a signiﬁcant difference be-
tween LP-211 and 5-CT in modulating the somatic sag ratio (Fig. 3D,
LP-211 1.04 ± 0.01, 5-CT 0.98 ± 0.01, p b 0.001). This suggests that
LP-211 is more potent than 5-CT in modulating HCN channels. Further-
more, LP-211 increased the sag ratio in sham animals (Fig. 3E, Sham
+ LP-211 1.05 ± 0.02, p b 0.05) to a similar extend as in CCI animals
(p = 0.59). Thus, the coupling of 5-HT7Rs to HCN channels is indepen-
dent from the pathological state.
3.3. Systemic injection of LP-211 reducesmechanical hypersensitivity and it
partially acts by modulation of the ACC
Next, we tested if the reversal of the pathological condition that we
observed on the cellular level by LP-211 in vitro had an inﬂuence on
the pain behavior of neuropathic animals. LP-211 can readily cross the
blood-brain-barrier and it has been shown to act in the central nervous
Fig. 1. 5-HT7 receptors and HCN channels co-localize in apical dendrites. A. Immunohistochemical staining of HCN1 (magenta, top) and 5-HT7Rs (green, middle) show a co-localization
(white, bottom) of the two proteins in the main apical dendrites of L5 pyramidal cells (arrows) in the rostral ACC. The lower plot shows the intensity distribution for HCN1 and 5-
HT7Rs across the cortical layers. The solid black line represents a single exponential ﬁt to the intensity proﬁle of the HCN channel distribution. The dashed black line represents a
Gaussian ﬁt to the intensity proﬁle of the 5-HT7R distribution. B. Enlarged view of apical dendrites shown in (A). C. Mechanical paw withdrawal threshold of mice subjected to CCI of
the left sciatic nerve (CCI, red; n = 7) and sham operated animals (Sham, blue; n = 6). Only the paw on the injured side displayed a reduction of the withdrawal threshold indicating
mechanical hypersensitivity. D. Length constant λHCN of HCN1 distribution was signiﬁcantly shorter for CCI as compared to sham operated animals. Error bars are S.E.M. ***p b 0.001. E.
Fluorescence intensity and widths of 5-HT7R distribution was not different for CCI and sham.
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system (Leopoldo et al., 2008). Testing the effect of LP-211 on mechani-
cal hypersensitivity induced by CCI, we found that a single i.p. injection
increased the mechanical withdrawal threshold whereas saline injec-
tions had no effect (Fig. 4A–D). The analgesic drug responsewas effective
after 30 min, reached a maximum between 90 and 150 min after injec-
tion and lasted at least 3 h. The maximal analgesic effect, expressed as
the drug effect, was 0.58 ± 0.13 (n = 7) and signiﬁcantly different
from the saline injected controls (drug effect control: 0.04 ± 0.07, n =
6; p b 0.01).
These results illustrate the potential therapeutic utility of LP-211 as
an analgesic drug, which can be systemically injected. Nevertheless,
the site of action has yet to be determined. Our ﬁndings that 5-HT7 re-
ceptors are highly enriched in the dendrites of L5 pyramidal neurons
in the ACC and that they co-localize and are functionally coupled with
HCN channels suggest an involvement of cortical sites to its action. To
determine the contribution of the ACC to the analgesic effect of systemic
injection of LP-211, we inhibited 5-HT7Rs speciﬁcally in the ACC by local
injection of the selective antagonist SB-269970 together with systemic
injection of LP-211 in CCI animals (Fig. 5). The block of 5-HT7Rs in the
ACC lead to a substantial reduction of the analgesic effect of LP-211
(Fig. 5C–E, drug effect, LP-211 + saline: 0.52 ± 0.08, n = 6; LP-211 +
Fig. 2. Effect of 5-HT7R activation by LP-211 on dendritic Ih and synaptic activity. A. Neurolucida reconstruction of a L5 pyramidal cell in the ACC showing the position of the dendritic
recording pipette. All recordings in this ﬁgure were performed on slices from CCI animals. B. Time course of the dendritic resting membrane potential (Vm) during bath application of
the 5-HT7 agonist LP-211 (27 nM) from the cell shown in B. Summary bar graph shows average values. C. Example traces of the voltage response induced by a hyperpolarizing current
step during baseline (red) and in the presence of LP-211 (blue) in a CCI animal. The average sag ratio showed a signiﬁcant increase after bath application of LP-211 (n = 5). D. Time
course of the EPSP amplitude during bath application of LP-211. Synaptic potentials were evoked by extracellular stimulation of the inner layer 1. Example traces show averaged EPSPs
before and after the application of LP-211. E. EPSP amplitude and coefﬁcient of variation (CV2) were not affected by LP-211 whereas the EPSP time integral was reduced (n = 10). F.
Paired EPSPs evoked at 50 Hz before and in presence of LP-211. Bar graph shows that the paired-pulse ratio was reduced by LP-211, indicating a reduction in temporal summation (n
= 10). Error bars are SEM. *p b 0.05, **p b 0.01.
Fig. 3. LP-211 is more potent than 5-CT. A. Neurolucida reconstruction of a L5 pyramidal
cell in the ACC showing the somatic recording conﬁguration. All recordings in this ﬁgure
were performed on slices from CCI animals. B. Somatic voltage response to a 300 pA
hyperpolarizing current step before (red) and after bath application of LP-211. Bar
graphs show an increase of the sag ratio by LP-211 (n = 18). C. Somatic voltage
response before (red) and after bath application of 5-CT. Bar graphs show that 5-CT
does not have an effect on the somatic sag ratio (n = 10). D. Normalized effect of LP-
211 and 5-CT on the sag ratio. E. Normalized effect of LP-211 on the sag ratio in sham
and CCI cells. Error bars are S.E.M. **p b 0.01 ***p b 0.001.
Fig. 4. Systemic LP-211 administration is analgesic for neuropathic pain. A. Experimental
design for the i.p. injection of LP-211 or saline in CCI animals. B. Time course of the
mechanical withdrawal threshold of mice subjected to CCI surgery and then tested after
saline (upper graph, n = 6) or LP-211 injection (lower graph, n = 7). C. Withdrawal
threshold of the injured paw normalized to the non-injured paw in saline (red) and LP-
211 treated groups. D. Bar graph showing the drug effect of saline and LP-211 treated
animals. Error bars are S.E.M. *p b 0.01.
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SB269970: 0.29 ± 0.08, n = 6; p b 0.05). Because local injections of SB-
269970 per se did not reduce mechanical hypersensitivity (Fig. 5E, drug
effect, saline:−0.03 ± 0.03 n= 4; SB-269970: 0.02 ± 0.04 n= 7), we
concluded that LP-211 directly activated 5-HT7 receptors in the ACC re-
ducing the response to mechanical stimulation of the injured hind paw.
As a control for the speciﬁcity of the blocking action of SB-269970 in
the ACC, saline or SB-269970 was injected into the region of the hind
paw representation in the primary somatosensory cortex (S1) after IP
injection of LP-211 (Fig. 5F–H). S1 is another important area involved
in pain processing and its modulation can inﬂuence pain behavior (Eto
et al., 2011). In contrast to the effect on the ACC, injection of SB-
269970 in S1 produced no change in the LP-211-induced reduction of
mechanical hypersensitivity (drug effect, saline: 0.54 ± 0.14, n = 7;
SB-269970: 0.51 ± 0.08, n = 8; p = 0.41).
In summary, these results conﬁrmed that LP-211 crossed the blood-
brain-barrier and that it exerted its effect partially in the ACC, but that it
is not generally acting on cortical areas involved in pain processing as
exempliﬁed by the absence of modulation in S1. Modulation of other
brain areas, for example the PAG or the raphe nuclei, as well as an inﬂu-
ence on the spinal cord, may account for the residual analgesic effect of
the drug.
3.4. LP-211 reverses the place escape/avoidance behavior in CCI animals
The ACC is essential for the processing of the emotional/affective
component of pain (Basbaum et al., 2009; Costigan et al., 2009; King et
al., 2009; Navratilova and Porreca, 2014). We therefore tested if LP-211
was also able to modulate the affective aspects associated with neuro-
pathic pain by using the place escape/avoidance paradigm (PEAP) (Fig.
6). This task requires processing in the ACC and it assesses the averseness
of neuropathic pain by exploiting the conﬂict between the desire to avoid
pain versus the safety of a preferred dark location (LaBuda and Fuchs,
2000; LaGraize et al., 2004). Animals were free to avoid a noxious stimu-
lus given to the injured hind paw in the dark compartment bymoving to
the light compartment, where the contralateral paw was mechanically
stimulated. Touching the corresponding paw was repeated every 15 s.
Since LP-211 reduced the mechanical withdrawal response as measured
with the von-Frey test, we used amuchmore rigid ﬁlament (number 12)
to clearly evoke a supra-threshold, nociceptive response in the injured,
left hind paw. CCI animals injected i.p. with a saline solution showed a
switch in the place preference from the dark to the light compartment
(Fig. 6A, B). In contrast, CCI animals injected with LP-211 did not show
this switch and they were not affected by the noxious stimulation in
the dark compartment anymore (relative time in light compartment,
Fig. 5. Effect of 5-HT7 antagonist injected in the ACC on LP-211 analgesia. A. Experimental
design for the i.p. injection of LP-211 and concomitant cortical injection of SB-269970, or
saline, in CCI animals and subsequent von Frey testing of mechanical sensitization. B.
Post hoc localization of the injection sites in the ACC by Alexa594 co-injection, ex vivo
clearing of the brain and reconstruction with 3D-ultramicroscopy. C. Time course of the
mechanical withdrawal threshold of mice subjected to CCI surgery and treated with LP-
211 after ACC injection of saline solution (upper graph, n = 6) or SB-269970 (lower
graph, n = 6). At time t =−60 min LP-211 was i.p. injected and at t =−45 min the
saline or SB269970 solution was injected. D. Withdrawal threshold of the injured paw
normalized to the non-injured paw after LP-211 injection and subsequent injection of
saline (blue) or SB-269970 (purple) in the ACC. E. Bar graph showing the drug effect of
LP-211 treated animals after ACC injection of saline or SB-269970 showing a signiﬁcant
effect of 5-HT7R blockade in the ACC on mechanical sensitization. Saline (n = 4) or SB-
269970 (n = 7) injection into the ACC without LP-211 had no analgesic effect by itself.
Error bars are S.E.M. *p b 0.05. F. Post hoc localization of the injection sites in S1 by
Alexa594 co-injection, ex vivo clearing of the brain and reconstruction with 3D-
ultramicroscopy. G. Withdrawal threshold of the injured paw normalized to the non-
injured paw after LP-211 injection and subsequent injection of saline (blue) or SB-
269970 (purple) in S1. H. Bar graph showing the drug effect of LP-211 treated animals
after S1 injection of saline or SB-269970 showing no effect of 5-HT7R blockade in the S1
on mechanical sensitization. Saline (n = 7) or SB-269970 (n = 8).
Fig. 6. LP-211 normalizes emotional pain behavior. A. Experimental design of the PEAP.
The mouse can freely move between a light and dark compartment. The injured paw is
stimulated in the dark compartment and the uninjured paw in the light compartment.
Stimulation of the corresponding paw was repeated every 15 s. The heat maps on the
right illustrate the time spent in each position 20–30 min after the beginning of the
stimulation in a saline (top) and LP-211 (10 mg/kg, bottom) treated animal. In the
saline treated condition, the animal spent less time in the preferred dark compartment.
B. The relative time spent in the light compartment is plotted as a function of time. 20–
30 min after the beginning of the stimulation of the corresponding hind paw, saline
treated CCI animals showed a switch in place preference (red, n = 7). This switch was
absent in LP-211 treated animals (blue, n = 8). The dashed line refers to the average of
the ﬁrst 10 min of the stimulation in the two conditions (37.3%). C. 10 min before the
beginning of the stimulation the animals were allowed to freely explore the two
compartments. The bar graph shows the relative time spent in the light compartment of
saline and LP-211 treated animals. Open circles indicate individual experiments. LP-211
injection had no inﬂuence on the overall anxiety level. D. Average velocity and total
distance covered of the animals during the recording period of 40 min. No differences
were found for these parameters in saline and LP-211 treated animals. Error bars are
S.E.M. *p b 0.05.
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20–30min after beginning of stimulation: saline: 48.2± 3.1%, n= 7; LP-
211: 27.6±3.4%, n=8; p b 0.05). LP-211 had no effect on the spontane-
ous exploratory behavior evaluated within 10min before the pawswere
stimulated (Fig. 6C; saline: 44.5± 3.7%; n= 7, LP-211: 43.9± 4.6%; n=
8; p N 0.05) ruling out general anxiolytic effects of LP-211 in this behav-
ioral paradigm. Furthermore, LP-211 did not exert sedative effects on the
animals since the average velocity (saline: 4.04 ± 0.38 cm/s; LP-211:
3.49 ± 0.37 cm/s; p N 0.05) and total distance covered (saline: 74.84
± 1.25 m; LP-211: 77.44 ± 0.80 m; p N 0.05) were not affected (Fig.
6D). These results show that activation of 5-HT7Rs by the blood-brain-
barrier-penetrant speciﬁc agonist LP-211 can alleviate the emotional/af-
fective pain behavior in mice experiencing neuropathic pain.
4. Discussion
On the cellular level chronic pain is established by persistent neuro-
nal plasticitywithin the pain transmitting system (Basbaumet al., 2009;
Costigan et al., 2009). Changes in cortical areas are of particular interest
to understand the cognitive, motivational and emotional/affective as-
pects and deﬁcits associated with the chronic pain condition
(Apkarian et al., 2009; Simons et al., 2014).
We recently demonstrated that activation of 5-HT7 receptors en-
hances HCN channel function and alleviates neuropathic pain, suggest-
ing that neuromodulation in the forebrain might be a potential strategy
for pain treatment. Here we studied the effects of LP-211, a highly spe-
ciﬁc 5-HT7R agonist that penetrates the blood-brain barrier. The use of
this compound allowed non-invasive treatment of animals with neuro-
pathic pain by acute i.p. injections. Our results revealed for the ﬁrst time
thatmechanical sensitization of the injured hind paw can be reduced by
systemic treatment with LP-211 and that at least part of the action can
be attributed to a mechanism modulating the ACC. In contrast, the pri-
mary somatosensory cortex, a brain area that is important for the local-
ization of nociception, was not involved in the action of LP-211. This
suggests that LP-211 is not globally dampening the activity of cortical
areas involved in pain processing. Nevertheless, it has to be determined
which other pain-related areas might also be contributing to the overall
analgesic effect. 5-HT7 receptors are expressed in the PAG and other
brain areas as well as the spinal cord (Ciranna and Catania, 2014). Pos-
sible analgesic effects by activation of 5-HT7Rs in these areas have pre-
viously been reported (Li et al., 2014; Lin et al., 2015). For instance,
although activation of 5-HT7Rs has no inﬂuence on acute pain behavior
in naïve animals (Yesilyurt et al., 2015), an up regulation of 5-HT7Rs in
the dorsal horn of the spinal cord in neuropathic pain and a local analge-
sic effect of another 5-HT7R agonist (E-57431) has been shown
(Brenchat et al., 2010). In contrast, the immunohistochemical staining
of 5-HT7Rs in our case did not indicate such a plastic change in receptor
expression in the ACC in the neuropathic pain condition. In general, ac-
tivation of 5-HT7Rs by descending serotoninergic pathways has been
shown to be necessary for stress-induced analgesia. Moreover, the
anti-hyperalgesic effects of morphine, of some antidepressants and
non-opioid analgesic drugs also depend on 5-HT7Rs (Dam et al., 2014;
Dogrul and Seyrek, 2006), suggesting that these receptors might be
the ﬁnal target of some established pain treatments aswell as of the en-
dogenous pain regulatory systems.
LP-211 completely abolished the pain-induced shift in place prefer-
ence in a place escape/avoidance paradigm. This behavioral assay de-
pends on the ACC and it is thought to be related to the emotional/
affective component of pain (LaBuda and Fuchs, 2000; LaGraize et al.,
2004). This behavioral test assesses the averseness of neuropathic
pain by exploiting the conﬂict between the desire to avoid pain versus
the safety of an enclosed, dark location, which is usually preferred by
the animal. Thus, we were able to show that LP-211 can reduce the
emotional distress associated with chronic pain. Our results are consis-
tent with previous ﬁndings reporting that LP-211 can modulate affec-
tive behavior and anxiety (Adriani et al., 2012) and extend these
ﬁndings to the modulation of pain averseness.
In the ACC, we were able to determine the mechanism of action of
LP-211 on the cellular level. 5-HT7R activation increases HCN function
via the stimulation of adenylate cyclase and an increase in cAMP levels
as has been demonstrated previously (Chapin and Andrade, 2001;
Santello and Nevian, 2015; Tang and Trussell, 2015), resulting in de-
creased temporal summation of EPSPs and thus decreased cellular excit-
ability of L5 pyramidal neurons. Importantly, we did not ﬁnd any
synapticmodulation suggesting that 5-HT7Rs are not involved in synap-
tic transmission. Previously, we have shown that there is also no inﬂu-
ence on inhibitory interneurons and L2/3 pyramidal neurons in the
ACC (Santello and Nevian, 2015). Alternative pathways downstream
of 5-HT7R activation could be through protein kinase A (PKA) or other
direct G-protein interactions (Perez-Garci et al., 2013). We have previ-
ously shown that the activation of 5-HT7Rs has no further inﬂuence on
cellular excitability when HCN channels are blocked, excluding an ap-
parent alternative mode of action in L5 pyramidal neurons in the ACC
(Santello and Nevian, 2015).
In light of a potential translational utility of LP-211, the speciﬁcity of
activating a particular 5-HT receptor subtype that decreases neuronal
excitability might be beneﬁcial compared to increasing 5-HT levels in
the brain globally with tricyclic antidepressants. Moreover, chronic LP-
211 treatment may cause 5-HT7Rs upregulation and therefore might
cause persistent beneﬁcial effects, as it has been shown in other patho-
logical models (Nativio et al., 2015; Ruocco et al., 2014).
The 5-HT7 receptor has been little studied so far, mainly due to the
lack of a speciﬁc agonist. The development of new brain-penetrant
and speciﬁc 5-HT7Rs agonists is nowhelping shedding light on the path-
ophysiological role of this receptor, which has been documented to be
present in several areas of the human nervous system including the an-
terior cingulate gyrus (Slassi et al., 2004). The results presented here to-
gether with the reported analgesic effects of activating 5-HT7Rs in the
spinal cord, point to a central role for this receptor in pain modulation
and suggest a novel and speciﬁc treatment strategy for chronic pain
that acts both on spinal and supra-spinal targets.
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